SCHEMBL6554915

SCHEMBL6554915

Cc1cc(C(=O)O)ccc1NC1(C(=O)CNC(=O)OCc2ccccc2)CCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 3/20 0.45
CTSS P25774 3/20 0.45
CTSL P07711 2/20 0.45
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
CTSK P43235 2/20 0.39
MAPK1 P28482 1/20 0.38
TBXA2R P21731 1/20 0.38
MAPT P10636 1/20 0.38
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
OPRK1 P41145 1/20 0.38
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6554457 0.80 CTSL (0.39) CTSBCTSSCTSLCTSK
SCHEMBL1554137 0.76 NPC1 (0.70) NPC1RAB9AALDH1A1L3MBTL1MAPT
SCHEMBL7557798 0.70 ALDH1A1 (0.47) CTSBCTSSCTSLALDH1A1NPSR1
SCHEMBL8274276 0.69 CTSL (0.52) CTSBCTSSCTSLNPC1RAB9A
SCHEMBL8274258 0.69 CTSL (0.52) CTSBCTSSCTSLNPC1RAB9A
SCHEMBL2793841 0.68 LMNA (0.55) CTSBCTSSCTSLALDH1A1NPSR1
SCHEMBL25252644 0.67 ALDH1A1 (0.57) CTSBCTSSCTSLALDH1A1NPSR1
SCHEMBL16590476 0.67 FKBP1A (0.60) CTSBCTSSCTSLNPC1RAB9A
SCHEMBL25247732 0.67 ALDH1A1 (0.54) CTSBCTSSCTSLALDH1A1LMNA
SCHEMBL4052066 0.66 ALDH1A1 (0.47) CTSBCTSSCTSLALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390357-A2 ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2004-02-25 EP disclosed
US-20020151534-A1 Antithrombotic compounds BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US disclosed
WO-2002062778-A2 ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151534-A1 Antithrombotic compounds SERPINC1, PF4, F2 CTSB 3002/4885CTSS 3765/4885CTSL 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.